The Shareholders Foundation announces that an investigation on behalf of investors in NASDAQ:AMED shares was launched over potential securities laws violations by Amedisys Inc and certain of its directors and officers in connection certain financial statements.
Investors who purchased shares of Amedisys Inc (NASDAQ:AMED), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation or call +1(858) 779 – 1554.
The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Amedisys Inc (NASDAQ:AMED) concerning whether a series of statements by Amedisys Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Amedisys Inc reported that its annual Total Revenue declined from over $1.24 billion in 2013 to over $1.20 billion and that its Net Loss of $96.18 million in 2013 turned to a Net Income of $12.78 million in 2014.
On May 28, 2015 Amedisys Inc announced that, on May 21, 2015, it received a Subpoena Duces Tecum (“Subpoena”) issued by the U.S. Department of Justice. Amedisys Inc said that the Subpoena requests the delivery of information regarding 53 identified hospice patients to the United States Attorney’s Office for the District of Massachusetts and that it also requests the delivery of documents relating to the Company’s hospice clinical and business operations and related compliance activities. The Subpoena generally covers the period from January 1, 2011, through the present.”
On June 16, 2015, NASDAQ:AMED shares closed at $ 39.18 per share.
Those who purchased shares of Amedisys Inc (NASDAQ:AMED) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego